| Accession |
PRJCA024692 |
| Title |
Durvalumab with gemcitabine-based chemotherapy as First Line Treatment in Patients with unresectable Biliary Tract Cancers |
| Relevance |
BTC |
| Data types |
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination with Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients with unresectable Biliary Tract Cancers (TopDouble) |
| Sample scope |
Multiisolate |
| Release date |
2024-03-26 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| AstraZeneca Investment (China) Co., Ltd.
|
|
D933AL00006
|
|
|
|
| Submitter |
huichuan
Sun (sun.huichuan@zs-hospital.sh.cn)
|
| Organization |
Zhongshan Hospital, Fudan University |
| Submission date |
2024-03-26 |
